ABIVAX Société Anonyme (ABVX)
NASDAQ: ABVX · Real-Time Price · USD
88.01
-2.22 (-2.46%)
At close: Oct 23, 2026, 4:00 PM EDT
87.56
-0.45 (-0.51%)
After-hours: Oct 23, 2026, 7:56 PM EDT
Company Description
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease.
The company was incorporated in 2013 and is headquartered in Paris, France.
ABIVAX Société Anonyme
| Country | France |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 98 |
| CEO | Marc M. de Garidel |
Contact Details
Address: 7-11 Boulevard Haussmann Paris, 75009 France | |
| Phone | 33 1 53 83 09 63 |
| Website | abivax.com |
Stock Details
| Ticker Symbol | ABVX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $11.60 |
| CIK Code | 1956827 |
| CUSIP Number | 00370M103 |
| ISIN Number | US00370M1036 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marc M. P. de Garidel M.B.A. | Chief Executive Officer and Director |
| Didier Blondel | EVice President, Chief Financial Officer and Board Secretary |
| Timothy P. Kelly M.B.A. | Chief Technical Officer |
| Patrick Malloy | Senior Vice President and Head of Investor Relations |
| Ida Hatoum | Chief People and Compliance Officer |
| James Berger | Global Head of Marketing |
| Pierre Courteille M.B.A. | Chief Business Officer |
| Hema Keshava | Senior Vice President of Finance |
| Chris Rabbat Ph.D. | Chief Medical Officer |
| Kevin Shan Ph.D. | Vice President and Global Head of Biometrics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 21, 2026 | F-6EF | Registration of American Depository Receipt shares, immediately effective |
| Sep 21, 2026 | 6-K | Report of foreign issuer |
| Aug 14, 2026 | SCHEDULE 13G/A | Filing |
| Aug 13, 2026 | SCHEDULE 13G/A | Filing |
| Jul 6, 2026 | SCHEDULE 13D/A | Filing |
| Jul 2, 2026 | 6-K | Report of foreign issuer |
| Jul 2, 2026 | 424B5 | Filing |
| Jul 1, 2026 | FWP | Free Writing Prospectus |
| Jun 30, 2026 | FWP | Free Writing Prospectus |
| Jun 30, 2026 | 424B5 | Filing |